| 1. |
Hay, R. J. (1996) Animal cells in culture, in Maintaining Cultures for Biotechnology and Industry (Hunter-Cevera, J. C. and Belt, A., eds.), Academic Press, London, pp. 161–178.
|
| |
| 2. |
Merten, O.W., Petres, S., and Couvé, E. (1995) A simple serum-free freezing medium for serum-free cultured cells. Biologicals
23:2, 185–189.
|
| |
| 3. |
Doyle, A. and Morris, C. B. (1994) Cryopreservation, in Cell & Tissue Culture: Laboratory Procedures (Doyle, A., Griffiths, J. B., and Newell, D. G., eds.), Wiley, Chichester, U.K., pp. 4C:1.1–4C:1.7.
|
| |
| 4. |
Quality of biotechnological products: derivation and characterization of cell substrates for the production of biotechnological/biological
products (1997) ICH, London.
|
| |
| 5. |
Points to consider in the characterization of cell lines used to produce biologicals (1993) CBER, FDA, Washington, DC.
|
| |
| 6. |
Production and quality control of monoclonal antibodies (1994) European Commission, Brussels.
|
| |
| 7. |
Requirements for use of animal cells as in vitro substrates for the production of biologicals (1997) WHO, Geneva.
|
| |
| 8. |
Tedder, R. S., Zuckerman, M. A., Goldstone, A. H., Hawkins, A. E., Fielding, A., Briggs, E. M., et al. (1995) Hepatitis B
transmission from contaminated cryopreservation tank. Lancet
346, 137–140.
|
| |
| 9. |
Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin (1997) ICH, London.
|
| |
| 10. |
Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997) CBER, FDA, Washington.
|
| |
| 11. |
Böedeker, B. G. D., Newcomb, R., Yuan, P., Braufman, A., and Kelsey, W. (1994) Production of recombinant factor VIII from
perfusion cultures: I. Large-scale fermentation, in Animal Cell Technology: Products of Today, Prospects for Tomorrow (Spier, R. E., Griffiths, J. B., and Berthold, W., eds.), Butterworth-Heinemann, Oxford, pp. 580–583.
|
| |
| 12. |
Froud, S. J., Birch, J., Mclean, C., Shepherd, A. J., and Smith, K. T. (1997) Viral contaminants found in mammalian cell lines
used in the production of biological products, in Animal Cell Technology: From Vaccines to Genetic Medicine (Carrondo, M. J. T., Griffiths, B., and Moreira, J. L. P, eds.), Kluwer, Dordrecht, pp. 681–686.
|
| |
| 13. |
Bebbington, C. R., Renner, G., Thomson, S., King, D., Abrams, D., and Yarranton, G. T. (1992) High level expression of a recombinant
antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Bio/technology
10, 169–175.
|
| |
| 14. |
Code of Federal Regulations 21, 610.12, FDA, Washington, DC.
|
| |
| 15. |
Wiebe, M. E., Becker, F., Lazar, R., May, L., Casto, B., Semense, M., et al. (1989) A multifaceted approach to assure that
recombinant tPA is free of adventitious virus, in Advances in Animal Cell Biology and Technology for Processes (Spier, R. E., Griffiths, J. B., Stephenne, J., and Crooy, P. J., eds.), Butterworths, Oxford, pp. 68–71.
|
| |
| 16. |
Quality of biotechnological products: analysis of the expression construct in cells used for production of r-DNA derived protein
products (1995) ICH, London.
|
| |